Cost Insights: Breaking Down AstraZeneca PLC and Evotec SE's Expenses

Unveiling Cost Dynamics: AstraZeneca PLC vs. Evotec SE

In the ever-evolving pharmaceutical landscape, understanding cost structures is pivotal. AstraZeneca PLC, a global biopharmaceutical leader, and Evotec SE, a prominent drug discovery company, present intriguing contrasts in their cost of revenue from 2014 to 2023. AstraZeneca's cost of revenue surged by approximately 115% from 2014 to 2021, peaking in 2021 with a notable 12.4 billion USD. This reflects its expansive R&D investments and strategic acquisitions. In contrast, Evotec SE, with a more modest scale, saw a steady increase, reaching its highest in 2023 with around 606 million USD, marking a tenfold rise since 2014. This growth underscores Evotec's expanding footprint in collaborative drug discovery. The data highlights AstraZeneca's robust financial muscle compared to Evotec's agile growth strategy, offering a fascinating glimpse into their operational priorities over the past decade.